Patents Examined by Claire Kaufman
  • Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases
    Patent number: 9518988
    Abstract: A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: December 13, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshit Lindzen, Yosef Yarden
  • Frizzled-binding agents and uses thereof
    Patent number: 9499630
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: November 22, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventor: Austin L. Gurney
  • Methods of using ERBB2 conjugate peptides
    Patent number: 9493542
    Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: November 15, 2016
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yan-Mei Tao, Shi-Wen Luo
  • DR5—FAP bispecific death receptor agonistic antibodies
    Patent number: 9481730
    Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: November 1, 2016
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau, Sylvia Herter, Christoph Lampert, Ekkehard Moessner, Pablo Umana, Inja Waldhauer
  • Use of decorin for increasing muscle mass
    Patent number: 9474782
    Abstract: The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: October 25, 2016
    Assignee: Association Francaise contre les Myopathies
    Inventors: Antoine Kichler, Daniel Scherman
  • IFN?R2 compositions and methods of inhibiting neuronal cell death
    Patent number: 9458427
    Abstract: A method of inhibiting ?-amyloid (A?) induced neuronal cell death includes administering to a neuronal cell exposed to a neurotoxic amount of A? a therapeutically effective amount of cell penetrating peptide (CPP). The CPP has an amino acid sequence that has at least 80% sequence identity to about 5 to about 41 consecutive amino acids of SEQ ID NO: 1.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: October 4, 2016
    Assignee: Case Western Reserve University
    Inventor: Shigemi Matsuyama
  • Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof
    Patent number: 9458238
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: October 4, 2016
    Assignee: Cancer Research Technology Limited
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
  • Method of treating rash in patients undergoing anti-EGFR therapy
    Patent number: 9428582
    Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 30, 2016
    Assignee: GENMAB A/S
    Inventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
  • Anti-apoptotic fusion proteins for reducing myocardial infarction size
    Patent number: 9388219
    Abstract: The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention also relates to a pharmaceutical composition comprising such a fusion protein, in particular for blocking apoptosis in a patient in need thereof. The invention also provides a polynucleotide encoding such a fusion protein, an expression vector comprising the polynucleotide and a host cell comprising the expression vector. In a further aspect, the invention relates to the use of any of theses materials for the preparation of a medicament for blocking apoptosis in a patient in need thereof.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: July 12, 2016
    Inventors: Ulrich Kunzendorf, Stefan Krautwald
  • Pharmacological chaperones for treating obesity
    Patent number: 9381194
    Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: July 5, 2016
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jian-Qiang Fan, Kenneth Valenzano, Gary Lee, Michel Bouvier, Patricia René
  • Methods for treating malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
    Patent number: 9371379
    Abstract: The present invention provides methods for treating malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2).
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 21, 2016
    Inventors: Gavin Thurston, Christopher Daly, Lisa Purcell Ngambo
  • ErbB3 binding antibody
    Patent number: 9346889
    Abstract: The present invention relates to an antibody, particularly a monoclonal antibody, which binds to the ErbB3 receptor, compositions comprising such an antibody as well as methods using such an antibody.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: May 24, 2016
    Assignee: MEDIAPHARMA S.R.L.
    Inventors: Raffaella Muraro, Stefano Iacobelli, Nicola Tinari, Sara Traini, Gianluca Sala
  • Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof
    Patent number: 9340596
    Abstract: Provided is a fusion protein comprising a tumor necrosis factor related apoptosis inducing ligand (TRAIL), integrin ligands of ?V?3 and ?V?5 and a linking peptide. Also provided are the expression method and simple separation and purification process for the production of the fusion protein which is soluble and has high content of the polymer, and use of the fusion protein for the manufacturing of a medicament for the treatment of tumor. The fusion protein has good tumor tissue targeting property, significantly enhanced anti-tumor effect, which can also reduce the dose of the needed protein for the target treatment effect, improve the bioavailability, reduce the treatment cost, decrease and overcome the potential toxic and side effects of the tumor necrosis factor-related apoptosis inducing ligand.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: May 17, 2016
    Assignee: NANJING UNIVERSITY
    Inventors: Zichun Hua, Lin Cao
  • Thyroid-stimulating hormone receptor polypeptide agonist glycoforms to treat metabolic syndrome
    Patent number: 9333241
    Abstract: TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: May 10, 2016
    Assignee: LipoLytics Therapeutics, LLC
    Inventor: James D. Kelly
  • Oxidative stress responsive apoptosis inducing protein eIF5A
    Patent number: 9321819
    Abstract: Secreted eIF5A protein which is useful for diagnosis, prevention, and treatment of various diseases induced by an oxidative stress.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: April 26, 2016
    Inventor: Yoshinori Seko
  • Antibodies against ROR1 and uses thereof
    Patent number: 9266952
    Abstract: The invention relates to antibodies for inducing cell death by the specific binding of (ROR1), domains thereof or nucleotide molecules encoding (ROR1). There are also provided methods involving and uses of the antibodies of the invention.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: February 23, 2016
    Assignee: KANCERA AB
    Inventor: Ingrid Teige
  • Remedies for pemphigus containing anti-Fas ligand antibodies
    Patent number: 9255150
    Abstract: The present invention refers to the use of FasL antagonists, e.g. of humanized antibodies directed against human Fas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL) for the prevention and/or treatment of skin diseases associated with keratinocytes acantholysis, particularly for the prevention and/or treatment of pemphigus.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: February 9, 2016
    Assignee: PINCELL SRL
    Inventors: Carlo Pincelli, Alessandra Marconi
  • Bispecific EGFRvIII x CD3 antibody engaging molecules
    Patent number: 9249217
    Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 2, 2016
    Assignees: Secretary, DHHS, Duke University
    Inventors: Darell D. Bigner, Chien-Tsun Kuan, John H. Sampson, Mingqing Cai, Bryan D. Choi, Ira H. Pastan
  • Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
    Patent number: 9234042
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: January 12, 2016
    Assignee: DELPHI GENETICS SA
    Inventors: Jean-Christophe Renauld, Muriel Lemaire, Laurie Dumoutier, Yannick Nizet, Alain Vanderplasschen, Laurent Gillet
  • Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
    Patent number: 9233171
    Abstract: The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 12, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Thomas Chittenden